A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

Abstract Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast cancer (TNBC). Atezolizumab with anthracycline- and taxane-based neoadjuvant chemotherapy has also shown increased pathological complete...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E. Claire Dees, Cesar A. Santa-Maria, Roisin M. Connolly, Jeremy Force, Alvaro Moreno-Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie M. Jones, Jason L. Weirather, Anita Giobbie-Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon, William E. Gillanders
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2022-12-01
Saila:	npj Breast Cancer
Sarrera elektronikoa:	https://doi.org/10.1038/s41523-022-00500-3
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!